[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100613593":3},{"organization":4,"outcomesModule":7,"designInfo":13,"detailedDescription":11,"studyPopulation":16,"armGroups":11,"interventions":17,"overallOfficials":11,"centralContacts":11,"locations":11,"responsibleParty":22,"collaborators":11,"id":24,"slug":11,"hasResults":25,"nctId":26,"briefTitle":27,"officialTitle":28,"acronym":11,"eligibilityCriteria":29,"healthyVolunteers":25,"sex":30,"minAge":11,"maxAge":11,"enrollmentInfo":31,"targetDuration":11,"studyType":34,"phases":11,"briefSummary":35,"conditions":36,"keywords":38,"overallStatus":44,"whyStopped":11,"lastUpdateSubmitDate":45,"lastUpdatePostDateStruct":46,"startDateStruct":49,"completionDateStruct":51,"leadSponsor":53,"locationsCount":11},{"fullName":5,"class":6},"Emergent BioSolutions","INDUSTRY",{"primaryOutcomes":8,"secondaryOutcomes":11,"otherOutcomes":11},[9],{"measure":10,"description":11,"timeFrame":12},"Number of individuals who developed inhalational anthrax and\u002For anthrax meningitis and received CYFENDUS for post exposure prophylaxis divided by the total number reported to have received CYFENDUS for post exposure prophylaxis.",null,"At least 12 months after containment of the mass exposure event",{"allocation":11,"interventionModel":11,"interventionModelDescription":11,"primaryPurpose":11,"observationalModel":14,"timePerspective":15,"maskingInfo":11},"CASE_ONLY","RETROSPECTIVE","The study population will include adults for which CYFENDUS is indicated (18 to 65 years of age), but it may include pediatric, pregnant, and geriatric populations if they are vaccinated with CYFENDUS based on public health recommendations as part of outbreak management.",[18],{"type":19,"name":20,"description":21,"armGroupLabels":11,"otherNames":11},"BIOLOGICAL","CYFENDUS","Intramuscular administration of two doses of Anthrax Vaccine Adsorbed, Adjuvanted",{"type":23,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100613593",false,"NCT07268612","Evaluation of Clinical Benefit and Safety Following CYFENDUS Administration for Post-Exposure Prophylaxis of Anthrax Disease.","A Phase 4 Retrospective Observational Study of CYFENDUS™ Anthrax Vaccine Among Individuals Who Received Post-Exposure Prophylaxis Vaccination During a Bacillus Anthracis Mass Exposure Event","Inclusion Criteria:\n\n* Individuals who received any dose of CYFENDUS vaccine (with or without concurrent recommended antibacterial regimen) for anthrax post exposure prophylaxis during an identified mass B. anthracis exposure event in the United States.\n\nExclusion Criteria:\n\n* Individuals who did not receive CYFENDUS for anthrax post exposure prophylaxis during an identified mass B. anthracis exposure event in the United States.","ALL",{"count":32,"type":33},250,"ESTIMATED","OBSERVATIONAL","The goal of this observational study is to evaluate the safety and clinical benefit of two doses of CYFENDUS vaccine when used with the concurrent recommended antibacterial regimen for post-exposure prophylaxis to prevent inhalational anthrax and\u002For anthrax meningitis.",[37],"Anthrax",[37,39,40,41,42,20,43],"Anthrax meningitis","cutaneous anthrax","gastrointestinal anthrax","inhalational anthrax","Anthrax vaccine adsorbed adjuvanted","NOT_YET_RECRUITING","2025-12-04",{"date":47,"type":48},"2025-12-08","ACTUAL",{"date":50,"type":33},"2035-11",{"date":52,"type":33},"2037-11",{"name":5,"class":6}]